PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Riad Salem, MD, MBA, Mark Yarchoan, MD - Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease
Go online to PeerView.com/WEZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern care of hepatocellular carcinoma (HCC) is increasingly reliant on collaboration between interventional radiology and oncology to select, combine, sequence, and transition between therapy options. In this activity, based on a recent webcast event, case-based discussions are used to explore best practices for managing patients through interdisciplinary collaboration. Experts discuss innovative immunotherapy and locoregional therapy options in earlier-stage disease, the transition to systemic therapy in advanced disease, and explore the latest clinical and safety data in immunotherapy-antiangiogenic regimens, dual checkpoint inhibitor approaches, and newer single-agent immune options. Upon completion of this activity, participants should be better able to: Cite current evidence supporting immunotherapy-based platforms in advanced and intermediate HCC; Integrate immunotherapy platforms into team-based, multidisciplinary management of intermediate- and advanced-stage HCC, including via clinical trial enrollment when appropriate; and Address safety, dosing, care coordination, and therapy delivery considerations when treating patients with HCC using multimodal management options.